The pursuit of a low-cost, noninvasive approach to early cancer screening is a common goal of medical researchers, and a team in Australia claims to have made significant progress in this area. The team has developed a breath test that can detect expiratory characteristics associated with cervical cancer, and the tool has shown high accuracy in early trials. < / P > < p > in the past few years, we have studied many promising breath tests for cancer. Many of these technologies work by analyzing the volatile organic compounds (VOCs) in our breath, which appear in unique patterns when our body’s metabolism is destroyed by disease. < / P > < p > efforts to detect and classify these unique respiratory based biomarkers have recently gained some optimistic momentum. Studies involving esophageal cancer and gastric cancer have yielded promising results. We have seen lung cancer respiratory testing and more general methods being introduced into clinical trials. < / P > < p > in the new study, from Flinders University in Australia, researchers focused on head and neck cancer. This accounts for six percent of all cancers and kills more than 300000 people worldwide each year. If the disease is found early, the treatment is often effective, and the late form of the disease will lead to poor prognosis. < / P > < p > & quot; our work found a unique VOCs feature in a cohort of patients in Australia that distinguishes head and neck cancer patients from non cancer patients, explains lead author Dr. Roger yazbek to new atlas. The cohort consisted of 181 patients with suspected early-stage head and neck cancer who had not yet received treatment. By analyzing VOCs in their exhalations using a selected ion tube mass spectrometer, the researchers were able to identify a specific pattern associated with head and neck cancer. < / P > < p > in the process of testing breath test, researchers found that it can accurately detect 80% of cancer and 86% of benign cases. These results were analyzed by biopsy and confirmed in another group of patients. A key advantage of our work is that we use an independent team to confirm the accuracy of our tests, yazbek said. &Even though the number of patients in this study is relatively small, the accuracy of the test is retained in this independent group of patients, which gives us more confidence in the availability of the test in clinical application. &From here on, researchers hope to build on these promising results and conduct larger trials involving more diverse groups of patients with different races, genders and cancer stages. If it turns out to be successful in a larger cohort, it can find ways to get into clinical use. < / P > < p > < p > & quot; our grand vision is a handheld device that can be used at the clinic to quickly provide doctors with information about whether a person has a suspected head and neck cancer, yazbek told us. Global Tech